Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Acquires $999,459.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall bought 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. The trade was a 20.47 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Immunome Price Performance

Immunome stock opened at $6.99 on Friday. The firm has a market capitalization of $607.79 million, a P/E ratio of -0.86 and a beta of 1.93. The stock has a fifty day moving average price of $9.50 and a two-hundred day moving average price of $11.33. Immunome, Inc. has a 52-week low of $6.90 and a 52-week high of $24.87.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. On average, equities research analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new stake in Immunome in the 3rd quarter valued at about $219,000. Charles Schwab Investment Management Inc. raised its position in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after purchasing an additional 302,916 shares during the last quarter. Cerity Partners LLC lifted its holdings in Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after buying an additional 5,043 shares in the last quarter. FMR LLC increased its stake in shares of Immunome by 0.3% in the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after buying an additional 13,757 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in shares of Immunome by 129.1% during the third quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock valued at $442,000 after acquiring an additional 17,053 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on IMNM shares. Guggenheim dropped their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Finally, Stephens reissued an “overweight” rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.